Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Ursodiol Capsules25-01-2021
25-01-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Credit Rating
We wish to inform you that India Ratings and Research (Ind-Ra) vide its letter dated January 21, 2021 has upgraded company's Long-Term Issuer Rating to 'IND A+' with a Stable Outlook from 'IND A' previously. You are requested to take the same on record.22-01-2021
Strides Pharma Science Ltd - 532531 - Shareholding for the Period Ended December 31, 2020
Strides Pharma Science Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here20-01-2021
Strides Pharma Science Ltd - 532531 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1422351 Name of the Signatory :- Manjula RamamurthyDesignation :- Company Secretary and Compliance Officer20-01-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets15-01-2021
Former HDFC Bank MD Aditya Puri joins biopharma company Strides as advisor
Aditya Puri said that he was looking forward to working with Kumar and building world-class institutions to produce high-quality affordable biotherapeutics and CDMO services08-01-2021
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aditya Puri joins as Advisor to the Strides Group & Director of Stelis Biopharma08-01-2021
Strides Pharma may get transferred to a clutch of investors as promoters plan to exit
Company's vaccine facility likely to go on stream in January30-12-2020
Trading pick of the Strides Pharma Science (853.8): Buy
Investors with a medium-term horizon can buy the stock of Strides Pharma Science at current levels. After registering a 52-week low at 271 in late M26-12-2020
Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 23, 2020 for Pronomz Ventures LLP23-12-2020